Home » Stocks » CNTB

Connect Biopharma Holdings Limited (CNTB)

Stock Price: $17.00 USD 0.60 (3.66%)
Updated Apr 9, 2021 4:00 PM EDT - Market closed
Market Cap 948.88M
Revenue (ttm) n/a
Net Income (ttm) -119.15M
Shares Out 55.82M
EPS (ttm) -2.13
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 9
Last Price $17.00
Previous Close $16.40
Change ($) 0.60
Change (%) 3.66%
Day's Open 16.52
Day's Range 16.22 - 17.15
Day's Volume 12,718
52-Week Range 15.29 - 23.29


Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEW YORK--(BUSINESS WIRE)--Deutsche Bank announced today its appointment as depositary bank for the Nasdaq-listed American Depositary Receipt program of Connect Biopharma Holdings Limited. Connect Bioph...

2 weeks ago - Business Wire

SAN DIEGO and TAICANG, China, March 23, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (the “Company”), a global clinical-stage biopharmaceutical company dedicated to improvi...

2 weeks ago - GlobeNewsWire

Last week was a busy one for the IPO market with 11 IPOs raising $3 billion, joined by 24 SPACs that brought another $8.4 billion to the table. Chinese IoT platform developer Tuya Inc (NYSE: TUYA) raise...

Other stocks mentioned: AFCG, FNCH, GANX, JWEL, NAPA, OLO, SNCY ...
2 weeks ago - Benzinga

SHANGHAI, March 19, 2021 /PRNewswire/ -- Qiming Venture Partners' portfolio company Connect Biopharma today listed on the Nasdaq with the stock code "CNTB". The issue price is US$ 17.00/ADS.

3 weeks ago - PRNewsWire

SAN DIEGO and TAICANG, China, March 18, 2021 -- Connect Biopharma Holdings Limited (the “Company”), a global clinical-stage...

3 weeks ago - GlobeNewswire

Connect Biopharma Holdings, a Chinese Phase 2 biotech developing therapies for T cell-driven inflammatory diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

1 month ago - NASDAQ

Connect Biopharma Holdings Limited has filed to go public with an IPO on the NASDAQ.

1 month ago - SEC

About CNTB

Connect Biopharma is a global clinical-stage biopharmaceutical company developing therapies for the treatment of inflammatory diseases with significant unmet medical need. We specialize in designing and developing product candidates that modulate the immune system, with a particular focus on T cells. Our lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis, or AD, and asthma. We have initiated a Phase 2b tr... [Read more...]

Pharmaceutical Preparations
IPO Date
Mar 19, 2021
Zheng Wei, Ph.D.
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

Financial numbers in millions CNY.
Financial Statements